This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Treatment of vaginal candidiasis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Principles of treatment:

  • application of topical antifungal agents for sufficient time to be effective
  • to avoid re-infection from sexual partner - sexual intercourse should be avoided until cure is complete
  • prevention of auto-infection from the bowel
  • the vulva must be kept cool and dry. This is achieved by careful hygiene, use of cotton rather than synthetic underwear and careful drying after washing vaginal area.

Treatment options (1):

  • clotrimazole 500mg pessary stat OR
  • fenticonazole 600mg pessary stat OR
  • clotrimazole 100mg pessary for 6 nights OR
  • oral fluconazole 150mg stat

If recurrent: fluconazole (induction/maintenance) (1)

  • 150mg every 72 hours for 3 doses THEN 150mg once a week

Note that oral treatment should not be given to either pregnant women or to nursing mothers (2).

Post-antibiotic candidal vulvovaginitis:

  • a study suggested that the use of oral or vaginal forms of lactobacillus did not prevent post-antibiotic candida vulvovaginitis (3)

Reference:

  1. Public Health England (June 2021). Managing common infections: guidance for primary care
  2. MeReC Bulletin (2004); 14 (4): 13-16.
  3. Pirotta M et al. Effect of lactobacillus in preventing post-antibiotic vulvovaginal candidiasis: a randomised controlled trial. BMJ 2004;329:548

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.